Document is current
Any future updates will be listed below
-
Authors
Doyle, Catherine
Lohmann, Ana Elisa
Iqbal, Nayyer
Henning, Jan-Willem
Kulkarni, Swati
Califaretti, Nadia
Hilton, John
Ferrario, Cristiano
Bouganim, Nathaniel
Mates, Mihaela
Guillemette, Stephanie
Leite, Ricardo
Caron, Marc-Andre
Thireau, Francois
Machado, Andres
Chia, Stephen https://orcid.org/0000-0001-7070-4386
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 4 December 2024
First Online: 23 January 2025
Declarations
:
: Ana Elisa Lohmann has received honoraria from La Roche-Posay, Novartis, Pfizer, AstraZeneca, Gilead Sciences. Support in kind from Epic Science and Merck. Support for clinical trial from Roche, Novartis, and AstraZeneca. Fellowship support from Eli Lilly and Knight Therapeutics. Jan-Willem Henning has received research grants from AstraZeneca, Pfizer, and Novartis and honoraria from AstraZeneca, Novartis, Pfizer, Gilead, Knight Therapeutics, and University of Toronto. Support as consulting fees and for participation on the advisory board from AstraZeneca, Novartis, Pfizer, Gilead, and Knight Therapeutics. Support for role as chair for Real Canadian Breast Cancer Alliance (Breast CA guideline and advocacy committee). Swati Kulkarni has received honoraria from Novartis. Nadia Califaretti has received honoraria for role as advisory board chair and co-chair as well as in the form of payments made to her medical corporation (no name provided). John Hilton has previously participated in advisory boards/consulted with Novartis on ribociclib and alpelisib. Cristiano Ferrario has received honoraria from AstraZeneca, Bayer, Janssen, Knights Therapeutics, Novartis, Merck, Roche, and Seattle Genetics and support for study conduct from Novartis, AstraZeneca, Bayer, Janssen, Merck, Pfizer, Roche, and Seattle Genetics. Nathaniel Bouganim has received honorarium from AstraZeneca, Novartis, Gilead, and Merck for breast cancer educational activities. Stephen Chia has received support from Novartis during the conduct of the Treat ER + ight trial as well as support for role in the advisory board from Eli Lilly, AstraZeneca, Pfizer, and Merck. Stephanie Guillemette, Ricardo Leite, and Marc-Andre Caron are employees of Novartis Pharmaceuticals Canada Inc. Francois Thireau and Andres Machado are employees of Translational Research in Oncology (TRIO). TRIO was contracted for the conduct of Treat ER + ight trial. Catherine Doyle, Nayyer Iqbal, and Mihaela Mates have no relevant financial or non-financial interests to disclose.
